Cytokinetics (CYTK) FDA Approvals

Cytokinetics logo
$53.17 -2.96 (-5.27%)
Closing price 11/16/2026 04:00 PM Eastern
Extended Trading
$52.97 -0.20 (-0.38%)
As of 08:33 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cytokinetics' Drugs in the FDA Approval Process

This section highlights FDA-related milestones and regulatory updates for drugs developed by Cytokinetics (CYTK). Over the past two years, Cytokinetics has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as Aficamten, CK-586, and omecamtiv. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. Select a button below to view the list of FDA events for that drug.

Aficamten FDA Regulatory Timeline and Events

Aficamten is a drug developed by Cytokinetics for the following indication: Symptomatic obstructive hypertrophic cardiomyopathy (oHCM). This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

CK-586 FDA Regulatory Events

CK-586 is a drug developed by Cytokinetics for the following indication: In Patients With Symptomatic Heart Failure With Preserved Ejection Fraction. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

Omecamtiv mecarbil FDA Regulatory Events

Omecamtiv mecarbil is a drug developed by Cytokinetics for the following indication: Novel cardiac muscle activator, patients with heart failure. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

Cytokinetics FDA Events - Frequently Asked Questions

In the past two years, Cytokinetics (CYTK) has not received FDA approval for any therapies. However, the company does have drugs under review or in active clinical development.

In the past two years, Cytokinetics (CYTK) has reported FDA regulatory activity for the following drugs: Aficamten, CK-586 and omecamtiv mecarbil.

The most recent FDA-related event for Cytokinetics occurred on November 16, 2026, involving Aficamten. The update was categorized as "FDA approved," with the company reporting: "Cytokinetics, Incorporated announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) updating the U.S. Prescribing Information for MYQORZO® (aficamten) to include data from MAPLE-HCM, the Phase 3 trial comparing MYQORZO and the standard-of-care beta-blocker metoprolol, each as monotherapy, in adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM)."

Current therapies from Cytokinetics in review with the FDA target conditions such as:

  • Symptomatic obstructive hypertrophic cardiomyopathy (oHCM) - Aficamten
  • In Patients With Symptomatic Heart Failure With Preserved Ejection Fraction - CK-586
  • Novel cardiac muscle activator, patients with heart failure - omecamtiv mecarbil
  • NDA: New Drug Application
  • ANDA: Abbreviated New Drug Application
  • sNDA: Supplemental New Drug Application
  • BLA: Biologics License Application
  • sBLA: Supplemental Biologics License Application
  • FDA Approved: Approved by the FDA
  • EMA: European Medicines Agency
  • CE Mark: European Union Certification
  • NMPA: China National Medical Products Administration
  • MHLW: Japanese Ministry of Health
  • FDA Meeting: Consultation with FDA
  • Pre-IND: Pre-Investigational New Drug Meeting
  • Breakthrough Therapy: Special FDA designation for promising therapies
  • Fast Track: Accelerated FDA approval pathway
  • Orphan Drug: Designation for rare disease treatments
  • RPD: Rare Pediatric Disease Designation
  • RMAT: Regenerative Medicine Advanced Therapy
  • DSMB Review: Data Safety Monitoring Board Review
  • IDMC Review: Independent Data Monitoring Committee
  • MAA: MHRA Marketing Authorization Application
  • RTF: Refusal to File (Rejected Application)
  • 510(k): FDA Clearance for Medical Devices
  • Rolling Submission: Staggered regulatory review process

FDA progress for NASDAQ:CYTK last updated on 11/16/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data.
From Our Partners